Drug Trial Radar · NCT00102310
YM443 in Subjects With Functional Dyspepsia
Last checked: Nov 19, 2026Latest source record: Jan 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Mar 10, 2004
Primary completion
Mar 11, 2006
Study completion Mar 11, 2006
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma US, Inc.
- First posted
- Jan 27, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
Conditions
- Indigestion
- Nausea
Interventions
YM443Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
Dr. Suresh Karne
Huntsville, Alabama
James Thrasher, MD
Little Rock, Arkansas
Dr. Dennis Riff
Anaheim, California
Dr. Peter Winkle
Cypress, California
Dr. Ramin Farsad
Encinitas, California
Dr. Prahalad Jajodia
Fresno, California
Dr. Gurmej Dhillon
Fresno, California
Dr. Steven Duckor
Orange, California
Dr. Theodor Feinstat
Roseville, California
Scott Levenson, MD
San Carlos, California
Dr. Michael Bennett
San Diego, California
Dr. William Snape
San Francisco, California
Dr. Abbass Shafii
Colorado Springs, Colorado
Dr. Julio Salcedo
Washington D.C., District of Columbia
Dr. Daniel Maico
Gainesville, Florida
Dr. Simon Behar
Hialeah, Florida
Wayne Schonfeld, MD
Hollywood, Florida
Dr. Stephen Palte
Atlanta, Georgia
Dr. Nathan Segall
Atlanta, Georgia
Azazuddin Ahmed, MD
Oak Brook, Illinois
Brian Covey, MD
Dubuque, Iowa
Dr. Richard McCallum
Kansas City, Kansas
Robert Braun, MD
Topeka, Kansas
Carroll Steinfeld, MD
Madisonville, Kentucky
David Dulitz, MD
Metairie, Louisiana
Dr. Bal Raj Bhandari
Monroe, Louisiana
Dr. Robert Hardi
Chevy Chase, Maryland
Dr. Braden Kuo
Boston, Massachusetts
Dr. Robert Lustig
Bridgewater, New Jersey
Dr. Rejendra Prasad Gupta
Trenton, New Jersey
Dr. Vitaly Fishbein
West Orange, New Jersey
Dr. Wieslaw Ignatowicz
Brooklyn, New York
Dr. Eugene Bonapace
Great Neck, New York
Dr. James Grendell
Mineola, New York
Dr. William Harlan
Asheville, North Carolina
Dr. John Poulos
Fayetteville, North Carolina
Dr. Peter Eweje
Jacksonville, North Carolina
Dr. Charles Barish
Raleigh, North Carolina
Dr. William Gramley
Wilmington, North Carolina
Dr. Robert Kindel
Cincinnati, Ohio
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.